Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Australia’s Strattera Under Fire By Ethics Panel Disclosure

This article was originally published in PharmAsia News

Executive Summary

An ethics committee said an Australian university was misled by a researcher when it agreed to a study of Strattera (atomoxetine), Eli Lilly Australia's treatment for attention deficit hyperactivity disorder. The ethics committee of Curtin University said the school relied on a researcher who told it the U.S. FDA had canceled a black box warning for the drug based on an increased risk of suicidal thoughts. The university, in turn, failed to disclose the extent of Lilly's involvement in the ADHD study it was conducting. The disclosures led some members of Parliament to call for a ban on the drug because of safety questions, but the government rejected the idea. One Parliament member said the Therapeutic Goods Administration had received 18 reports of suicidal thoughts after taking Strattera, among 56 reports of adverse reactions. (Click here for more

You may also be interested in...

COVID-19 Vaccine Could Cost As Little As $10 A Dose, Says Janssen

Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.

Austria’s Apeiron To Attack COVID-19 At Its Entry Point

Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark. 


Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics

Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts